Background
==========

In 2016, with approximately 246 660 newly diagnosed cases and 40 450 deaths in the United States, breast cancer (BC) is still reported to be the most common cancer in women worldwide \[[@b1-medscimonit-23-5090]\]. In spite of the remarkable progress made during recent decades, approximate 20% of patients with BC still suffer from recurrence or distant metastasis within 5 years due to diagnosis at advanced stage \[[@b2-medscimonit-23-5090]\]. Therefore, represented by the liquid biopsy (such as circulating tumor cells, circulating DNA, circulating miRNA, circulating lncRNA, and exosome), some newly developed diagnostic biomarker have been used to screen cancer at an early stage; however, their clinical use is still limited due to their uncertain role and high costs \[[@b3-medscimonit-23-5090],[@b4-medscimonit-23-5090]\]. Accumulating evidence demonstrates that cancer-related systemic inflammation plays a significant role in the development and progression of several neoplastic diseases, including BC \[[@b5-medscimonit-23-5090]\]. Furthermore, along with the physical immune response, several inflammatory molecules in the peripheral blood have been verified to be overexpressed by tumor cells as a response to systemic inflammation, including C reactive protein, white cell counts, neutrophil, platelet count, and platelet-to-lymphocyte ratio \[[@b6-medscimonit-23-5090],[@b7-medscimonit-23-5090]\].

Red blood cell distribution width (RDW), reflecting the size variability of circulating erythrocytes, has recently been shown to be associated with chronic inflammation, which is a key determinant of disease progression and survival in various cancers \[[@b8-medscimonit-23-5090]--[@b10-medscimonit-23-5090]\]. Mean platelet volume (MPV) is a simple measurement of the average size of platelets, and the results are often used to make inferences about platelet production in bone marrow or platelet destruction problems. Elevated MPV usually leads to thrombocytosis in the neoplasms \[[@b11-medscimonit-23-5090]\]. Other inflammatory markers derived from the routine blood test are the neutrophils/lymphocytes ratio (NLR) and platelet count/lymphocytes ratio (PLR). Neutrophils are reported to have the potential to promote adhesion and seeding of circulating tumor cells to distant organ sites by secreting circulating growth factors such as vascular endothelial growth factor (VEGF) and proteases \[[@b12-medscimonit-23-5090],[@b13-medscimonit-23-5090]\]. In contrast, lymphocytes demonstrate the host immune response to malignancy through inducing cancer cell death and inhibiting tumor cell proliferation and migration \[[@b14-medscimonit-23-5090]\]. In this regard, hematological parameters in the routine blood test have the potential to serve as a marker for reflecting cancer-related inflammation during disease progression. Therefore, we performed this study and retrospectively analysis to assess whether hematological parameters can be used as an adjuvant tool to distinguish individuals with BC patients from healthy individuals. We further examined the correlation between levels of the selected parameters and the clinicopathological characteristics of the 110 BC patients.

Material and Methods
====================

Sample collection and ethics statement
--------------------------------------

This retrospective study, conducted between July 2014 and April 2015, included 110 BC patients hospitalized at Zhongnan Hospital of Wuhan University. The study included newly diagnosed primary and metastatic BC cases that had not received any treatments likely to affect hematological parameters. The control group was 76 healthy controls randomly selected from the Medical Examination Center who were there for routine checkups during the same period. Data regarding patients' demographics and laboratory values were retrospectively reviewed through hospital medical database records. None of the subjects in the control group had any recorded history of malignancies and were matched to the cases in terms of age (P=0.1028) and sex (female). The clinical characteristics and laboratory data of the study population are summarized in [Tables 1](#t1-medscimonit-23-5090){ref-type="table"} and [2](#t2-medscimonit-23-5090){ref-type="table"}. Ethics approval for the use of human subjects was obtained from the Ethics Committee of the Zhongnan Hospital of Wuhan University.

Blood assessment
----------------

Blood values had been taken into consideration at the time of diagnosis before administration of any treatment when patients were admitted to the hospital. Venous blood specimens were drawn into sterile standard tubes containing ethylene diamine tetraacetic acid (EDTA) as an anticoagulant and evaluated within 1 h after venipuncture using a Beckman Coulter UniCel DxH800 hematology analyzer. PC, RDW, WBC, MPV, NLR, and PLR values were then obtained directly from the routine blood tests through the medical database.

Statistical analysis
--------------------

All data analyses were performed using SPSS version 17.0 (SPSS, Inc. Chicago, IL, USA) and data are presented as mean ±standard deviation (SD). For comparisons, the *t* test (2-tailed), one-way analyses of variance (ANOVA), and Mann-Whitney U test were performed based on the normality of the distribution as checked by the Shapiro-Wilk test. Receiver-operating characteristics (ROC) curve analysis was further performed to identify optimum cut-off values of selected hematological parameters. Logistic regression analysis was carried out to check the correlation between MPV value and the risk of BC lymph node metastasis. P value less than 0.05 was considered statistically significant.

Results
=======

Comparisons between BC group and control group
----------------------------------------------

A total of 110 BC patients with newly confirmed BC and 78 healthy individuals were enrolled into this retrospective study. The laboratory blood parameters of BC patients and control group are shown in [Table 1](#t1-medscimonit-23-5090){ref-type="table"}. The levels of RDW, MPV, NLR, and PLR in the breast cancer group were significantly higher than in the control group (P\<0.05), but age distribution, PC, and WBC were not significantly different (P\>0.05) ([Table 1](#t1-medscimonit-23-5090){ref-type="table"}). ROC curve analysis showed that the AUCs of RDW, MPV, NLR, and PLR were 0.975, 0.810, 0.628, and 0.591, respectively ([Figure 1](#f1-medscimonit-23-5090){ref-type="fig"}). Specifically, the sensitivity of RDW was 99.09% (CI: 95.04% to 99.98%) and its specificity was 92.31% (84.01% to 97.12%) when the cut-off value was 12.25%, which exhibited the best differential diagnosis potential and could be used as an adjuvant tool for BC screening.

Subgroups analysis of BC patients
---------------------------------

Subgroup analyses based on age, tumor size, estrogen receptor, progesterone receptor, her-2, lymph node metastasis, WHO stage, and Ki-67 proliferation index were also conducted to analyze the correlation between selected hematological parameters and the clinical characteristics of BC patients. As shown in [Table 2](#t2-medscimonit-23-5090){ref-type="table"}, the MPV value in the lymph node metastasis group was significantly higher than in the group without lymph node metastasis (P=0.04), and MPV in patients with Ki-67\>15% is significantly higher than in those with Ki-67≤15 (P=0.0015), but there was no significant difference in PC, RDW, WBC, NLR, and PLR in each subgroup (P\>0.05). Multivariate logistic regression analysis was further performed to verify whether the MPV value was independently correlated with breast cancer metastasis status. ER, PR, HER-2, RDW, MPV, NLR, and PLR were considered as independent variables. Measurement data were divided according to quartile level of the selected parameters ([Table 3](#t3-medscimonit-23-5090){ref-type="table"}). The results demonstrated that MPV was an independent risk factor (OR=0.164, p=0.028) for lymph node metastasis in BC patients ([Table 4](#t4-medscimonit-23-5090){ref-type="table"}).

Discussion
==========

Breast cancer is still the most common cancer in women and ranks as the second cause of cancer-related deaths in the world \[[@b1-medscimonit-23-5090]\]. Therefore, early detection and control of lymph node metastasis has become an important part of breast cancer prevention and treatment.

Studies have shown that long-standing inflammation is closely related to the occurrence and development of tumors \[[@b15-medscimonit-23-5090],[@b16-medscimonit-23-5090]\]. Inflammatory breast cancer is a particular type of breast cancer which does not present as a lump, sometimes resulting in a delay in diagnosis \[[@b17-medscimonit-23-5090]\]. Therefore, it should be a primary goal of modern medicine to overcome the diagnostic problems and limitations for cancer patients. Hematological parameters in the noninvasive routine blood test have long been considered as markers for systemic inflammatory response \[[@b18-medscimonit-23-5090],[@b19-medscimonit-23-5090]\]. WBC and MPV are routinely measured hematological parameters and have been reported to be higher in patients with malignancies of the pancreas and liver in comparison with healthy controls \[[@b20-medscimonit-23-5090]\]. Recently, more attention has been focused on RDW, NLR, and PLR. Seretis et al. \[[@b21-medscimonit-23-5090]\] revealed that elevated RDW may indicate breast cancer with bone marrow infiltration, which may result in erythroid hematopoietic stem cell proliferation defect whereby a large volume of immature red blood cells is released into the peripheral blood in advance, which results in increased red blood cell size heterogeneity and RDW \[[@b8-medscimonit-23-5090]\]. Some investigators also demonstrated that higher RDW levels might reflect underlying chronic inflammation, which can result in higher cardiovascular risk \[[@b22-medscimonit-23-5090]\]. On the other hand, breast cancer-induced anemia can cause secondary elevated RDW \[[@b22-medscimonit-23-5090]\]. The diagnostic value of MPV, NLR, and PLR in distinguishing gastric cancer patients and healthy people has been reported \[[@b23-medscimonit-23-5090]\]. MPV is a platelet volume index directly reflecting platelet function state \[[@b24-medscimonit-23-5090]\]. Our results indicate that, compared to healthy individuals, MPV values in breast cancer patients were also significantly increased, which is consistent with previous research conducted in gastric cancer \[[@b25-medscimonit-23-5090]\]. Other inflammatory markers, such as PLR and NLR, has been proposed as reliable clinical diagnostic criteria in various types of cancer \[[@b26-medscimonit-23-5090]--[@b29-medscimonit-23-5090]\], and this was further verified in this retrospective study.

Conclusions
===========

The routine blood test is the most accessible and fundamental examination, which has long been proposed as an essential assistant tool for disease diagnosis. Our results show that RDW, MPV, NLR, and PLR can be effective in distinguishing breast cancer patients from healthy individuals. Among them, RDW is the most effective indicator, thus making it possible to assist physicians in the early diagnosis of BC in combination with other tests. Furthermore, MPV is a convenient and inexpensive laboratory index that has value in evaluating axillary lymph node metastasis and Ki-67 proliferation index in breast cancer, and could serve as a new biomarker for prognosis evaluation of BC patients. However, our study has limitations, including its small sample size and single-center design, and our results need to be verified by large-scale clinical studies with follow-up study. However, to the best of our knowledge, this study is the first to provide comprehensive insights into hematological parameters of routine blood testing in BC patients.
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![ROC curve analysis of RDW, MPV, NLR, and PLR. RDW -- red blood cell distribution width; MPV -- mean platelet volume; NLR -- neutrophils/lymphocytes ratio; PLR -- platelets count/lymphocytes ratio.](medscimonit-23-5090-g001){#f1-medscimonit-23-5090}

###### 

Demographics and hematological parameters of the study populations

  ----------------------------------------------------------------------
                   Breast cancer patients\   Control group\   P-value
                   n=110                     n=78             
  ---------------- ------------------------- ---------------- ----------
  Age (year)       54.34±12.28               51.54±10.37      0.1028

  PC (×10^9^/l)    206.20±52.93              218.50±43.67     0.0934

  MPV (fl)         9.11±1.29                 7.68±1.73        \<0.0001

  RDW (%)          13.45±1.14                11.39±0.67       \<0.0001

  WBC (×10^9^/l)   6.30±2.20                 6.396±1.43       0.7251

  NLR              2.60±2.47                 1.86±0.51        0.0094

  PLR              126.40±48.68              111.10±29.50     0.0142
  ----------------------------------------------------------------------

PC -- platelets count; MPV -- mean platelet volume; RDW -- red blood cell distribution width; WBC -- white blood cell count; NLR -- neutrophils/lymphocytes ratio; PLR -- platelets count/lymphocytes ratio.

###### 

Relationship between selected hematological parameters and clinical characteristics of BC patients.

  Clinical characteristic        No.of case   PC (×10^9^/l)   MPV (fl)   RDW (%)     WBC (×10^9^/l)   NLR           PLR                                                          
  ------------------------------ ------------ --------------- ---------- ----------- ---------------- ------------- ------ ------------ ------ ----------- ------ -------------- ------
  **Age (year)**                                                                                                                                                                 
   ≤50                           44           207.50±54.24    0.82       9.12±1.20   0.94             13.34±1.26    0.41   5.98±1.28    0.22   2.53±1.41   0.80   131.30±48.50   0.39
   \>50                          66           205.20±52.43               9.10±1.35                    13.52±1.07           6.51±2.62           2.65±2.98          123.10±48.90   
  **Tumor size (cm)**                                                                                                                                                            
   ≥2                            47           207.50±58.03    0.41       9.05±1.36   0.90             13.46±1.15    0.93   6.05±1.2     0.93   2.12±0.85   0.54   118.40±42.90   0.79
   \<2                           28           196.30±55.42               9.09±1.18                    13.43±1.22           6.02±1.48,          2.28±1.35          121.80±65.55   
  **Intrinsic subtype**                                                                                                                                                          
   Luminal A                     48           207.70±51.75    0.38       9.00±1.25   0.43             13.51±1.05    0.18   6.31±2.93    0.95   2.80±3.38   0.89   129.80±41.09   0.27
   Luminal B                     13           197.80±37.93               9.12±1.37                    13.08±0.47           6.44±1.72           2.50±2.00          112.50±41.80   
   HER2 overexpressing           7            201.00±70.70               9.84±2.21                    14.36±1.99           5.76±1.77           1.99±0.74          118.00±50.52   
   Triple negative               17           215.8±56.32                8.97±0.74                    13.46±1.60           6.33±1.44           2.81±1.25          146.20±68.44   
  **Estrogen receptor**                                                                                                                                                          
   Positive                      74           205.00±51.24    0.79       9.01±1.20   0.22             13.33±0.87    0.12   6.37±2.48    0.59   2.65±2.89   0.79   123.50±45.22   0.42
   Negative                      33           207.90±53.62               9.43±1.47                    13.71±1.62           6.12±1.47           2.50±1.27          131.80±56.59   
  **Progesterone receptor**                                                                                                                                                      
   Positive                      65           197.50±43.98    0.05       9.19±1.32   0.52             13.39±0.93    0.5    6.36±2.58    0.68   2.73±3.07   0.50   121.30±42.92   0.24
   Negative                      43           217.3±60.36                9.02±1.26                    13.54±1.43           6.18±1.50           2.34±1.16          132.60±56.3    
  **Her-2**                                                                                                                                                                      
   Positive                      21           199.30±48.66    0.42       9.40±1.65   0.20             13.49±1.32    0.98   6.22±1.68    0.87   2.32±1.62   0.48   114.30±42.68   0.11
   Negative                      65           209.80±52.65               8.99±1.14                    13.50±1.202          6.32±2.61           2.80±2.96          134.10±49.64   
  **Lymph node metastasis**                                                                                                                                                      
   Yes                           37           203.20±62.00    0.85       9.52±1.40   0.04\*           13.38±1.04    0.95   6.35±3.17    0.73   2.78±3.84   0.46   123.40±48.79   0.98
   No                            49           205.40±47.89               8.98±1.23                    13.37±1.05           6.17±1.59           2.33±1.24          123.00±49.05   
  **WHO stage**                                                                                                                                                                  
   I                             4            235.80±27.29    0.34       8.60±0.85   0.50             13.68±0.81    0.70   5.73±0.85    0.72   2.35±0.73   0.96   151.00±28.14   0.43
   II                            61           204.40±53.74               9.05±1.39                    13.26±0.85           6.27±2.63           2.72±3.12          126.60±46.70   
   III                           15           192.90±46.26               9.41±1.33                    13.27±1.32           6.72±1.60           2.80±1.74          117.00±50.03   
  **Ki67 proliferation index**                                                                                                                                                   
   ≤15                           31           219.20±38.83    0.07       8.50±0.91   \<0.01\*         13.29±0.73    0.36   6.24±1.49    0.90   2.27±1.35   0.37   125.90±43.40   0.99
   \>15                          76           199.30±55.61               9.37±1.35                    13.51±1.29           6.30±2.46           2.75±2.84          126.10±51.27   

###### 

Value assignments of RDW, MPV, NLR and PLR.

        Value assignments                      
  ----- ------------------- -------- --------- ----------
  RDW   \<12.70             12.70−   13.20−    \>13.70
  MPV   \<8.30              8.30−    8.90−     \>9.73
  NLR   \<1.65              1.65−    2.10−     \>2.70
  PLR   \<91.36             91.36−   114.43−   \>156.63

RDW -- red blood cell distribution width; MPV -- mean platelet volume; NLR -- neutrophils/lymphocytes ratio; PLR -- platelets count/lymphocytes ratio.

###### 

Multivariate logistic regression analysis of risk factors for lymph node metastasis of BC patients.

  Factor     B        S.E.    Wald    df   Sig.                                                        Exp(B)   95% CI for Exp(B)
  ---------- -------- ------- ------- ---- ----------------------------------------------------------- -------- -------------------
  ER         −0.632   0.852   0.550   1    0.458                                                       0.531    0.100\~2.826
  PR         0.811    0.817   0.984   1    0.321                                                       2.249    0.453\~11.157
  HER-2      −0.781   0.699   1.247   1    0.264                                                       0.458    0.116\~1.803
  RDW        0.377    0.776   0.236   1    0.627                                                       1.458    0.318\~6.681
  MPV        −1.809   0.823   4.830   1    0.028[\*](#tfn3-medscimonit-23-5090){ref-type="table-fn"}   0.164    0.033\~0.822
  NLR        1.310    0.929   1.990   1    0.158                                                       3.706    0.600\~22.880
  PLR        −1.001   0.963   1.080   1    0.299                                                       0.367    0.056\~2.428
  Constant   0.882    0.846   1.087   1    0.297                                                       2.416    

Indicates statistical significance.

ER -- estrogen receptor; PR -- progesterone receptor; HER-2 -- human epidermal growth factor receptor-2; RDW -- red blood cell distribution width; MPV -- mean platelet volume; NLR -- neutrophils/lymphocytes ratio; PLR -- platelets count/lymphocytes ratio.
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